The EHA 2026 presentation on June 14 is the key catalyst — watch for additional efficacy durability and safety details. The small sample (n=12) and short follow-up limit conviction; a larger Phase 2/3 trial is needed to confirm. For now, this is a positive early signal for Legend's pipeline beyond CARVYKTI.
Price Chart
Executive Summary
Legend Biotech announced promising Phase 1 data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, showing 100% ORR and 83.3% CR at dose level 2 in relapsed/refractory B-NHL, with no DLTs or SAEs. The data will be presented at EHA 2026 (June 11-14), providing a near-term catalyst. This is an early-stage, small-sample (n=12) readout, but the novel off-the-shelf approach could expand CAR-T access if confirmed in larger trials.
Key Facts
- Phase 1 data for LB2501 (in vivo CAR-T) shows 100% ORR (6/6) and 83.3% CR (5/6) at dose level 2 in R/R B-NHL
- No DLTs, SAEs, ICANS, or Grade ≥3 CRS observed; all CRS ≤ Grade 2
- CAR-T cells detected in peripheral blood for up to 116 days without lymphodepletion
- Data to be presented at EHA 2026 late-breaking session on June 14, 2026
- LB2501 is built on the proprietary TaVec lentiviral vector platform
- Median follow-up at DL2 was only 2.2 months (range 2.0–3.8); durability is early
Financial Impact
No financial data provided; early-stage pipeline readout with no revenue impact. Potential market expansion for in vivo CAR-T if successful.
Risk Factors
- Very early-stage data (n=12, median follow-up 2.2 months) — durability and larger-sample results unknown
- In vivo CAR-T is a novel modality with unproven long-term safety and manufacturing scalability
- Competition from other in vivo CAR-T approaches (e.g., Capstan, Sana) and approved CAR-T products
- No financial or regulatory milestones provided; clinical risk remains high
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305321 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 6-K | $19.80 | awaiting T+20 | — | $21.56 (+8.89%) |
Oct 13, 2026 14d ago | 6-K | $17.88 | awaiting T+20 | — | $21.56 (+20.58%) |
Sep 29, 2026 28d ago | 144 | $18.82 $21.16 | ▲ +12.41% | ▲ +11.75% | $21.56 (+14.56%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $21.56 (+12.82%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $21.56 (+12.82%) |
Sep 15, 2026 6w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $21.56 (+22.01%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $21.56 (+16.35%) |
Aug 11, 2026 11w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $21.56 (−1.24%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $21.56 (−11.88%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $21.56 (+11.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers